Financial reports
10-Q
2024 Q3
Quarterly report
8 Feb 24
10-Q
2024 Q2
Quarterly report
2 Nov 23
10-Q
2024 Q1
Quarterly report
8 Aug 23
ARS
2023 FY
Annual report to shareholders
16 Jun 23
10-K
2023 FY
Annual report
22 May 23
10-Q
2023 Q3
Quarterly report
7 Feb 23
10-Q
2023 Q2
Quarterly report
8 Nov 22
10-Q
2023 Q1
Quarterly report
10 Aug 22
10-K
2022 FY
Annual report
25 May 22
10-Q
2022 Q3
Quarterly report
8 Feb 22
Current reports
8-K
Haemonetics Corporation Completes Acquisition of Attune Medical
1 Apr 24
8-K
Haemonetics Announces Definitive Agreement to Acquire Attune Medical
5 Mar 24
8-K
Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2024 Results; Updates Fiscal 2024 Guidance
8 Feb 24
8-K
Other Events
12 Dec 23
8-K
Haemonetics Reports Second Quarter and First Half Fiscal 2024 Results; Updates Fiscal 2024 Guidance
2 Nov 23
8-K/A
Financial Statements and Exhibits
12 Oct 23
8-K
Entry into a Material Definitive Agreement
10 Oct 23
8-K
Haemonetics Reports First Quarter Fiscal 2024 Results; Updates Fiscal 2024 Guidance
8 Aug 23
8-K
Departure of Directors or Certain Officers
7 Aug 23
8-K
Results of Operations and Financial Condition
11 May 23
Registration and prospectus
S-8
Registration of securities for employees
11 Aug 23
POS AM
Prospectus update (post-effective amendment)
30 Jul 19
S-8
Registration of securities for employees
30 Jul 19
S-8
Registration of securities for employees
5 Feb 18
S-8
Registration of securities for employees
14 Nov 14
S-8
Registration of securities for employees
1 Jun 12
SC TO-T/A
Third party tender offer statement (amended)
1 Apr 10
SC TO-T/A
Third party tender offer statement (amended)
25 Mar 10
SC TO-T/A
Third party tender offer statement (amended)
18 Mar 10
SC TO-T/A
Third party tender offer statement (amended)
11 Mar 10
Proxies
DEFA14A
Additional proxy soliciting materials
16 Jun 23
DEF 14A
Definitive proxy
16 Jun 23
DEFA14A
Additional proxy soliciting materials
17 Jun 22
DEF 14A
Definitive proxy
17 Jun 22
DEFA14A
Additional proxy soliciting materials
17 Jun 21
DEF 14A
Definitive proxy
17 Jun 21
DEFA14A
Additional proxy soliciting materials
30 Jun 20
DEFA14A
Additional proxy soliciting materials
8 Jun 20
DEF 14A
Definitive proxy
8 Jun 20
DEFA14A
Additional proxy soliciting materials
12 Jun 19
Other
SD
Conflict minerals disclosure
30 May 23
SD
Conflict minerals disclosure
26 May 22
SD
Conflict minerals disclosure
28 May 21
SD
Conflict minerals disclosure
29 May 20
EFFECT
Notice of effectiveness
12 Aug 19
SD
Conflict minerals disclosure
30 May 19
CT ORDER
Confidential treatment order
19 Feb 19
SD
Conflict minerals disclosure
30 May 18
CT ORDER
Confidential treatment order
28 Aug 17
NO ACT
No action letter
5 Jun 17
Ownership
4
Anila Lingamneni
17 Apr 24
4
Christopher Simon,
13 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Neuberger Berman Group LLC
13 Feb 24
SC 13G/A
Capital Research Global Investors
9 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G/A
BlackRock Inc.
23 Jan 24
4
Roy Galvin
3 Nov 23
4
Michelle L Basil
24 Oct 23
4
Stewart W Strong
24 Oct 23